452 related articles for article (PubMed ID: 26887348)
41. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
42. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
43. Association between KRAS mutation and lung metastasis in advanced colorectal cancer.
Pereira AA; Rego JF; Morris V; Overman MJ; Eng C; Garrett CR; Boutin AT; Ferrarotto R; Lee M; Jiang ZQ; Hoff PM; Vauthey JN; Vilar E; Maru D; Kopetz S
Br J Cancer; 2015 Feb; 112(3):424-8. PubMed ID: 25535726
[TBL] [Abstract][Full Text] [Related]
44. Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update.
O Connor JM; Sanchez Loria F; Ardiles V; Grondona J; Sanchez P; Andriani O; Fauda M; Brancato F; Huertas E; Alvarez F; de Santibañes E
Future Oncol; 2019 Sep; 15(27):3149-3157. PubMed ID: 31426677
[No Abstract] [Full Text] [Related]
45. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
[TBL] [Abstract][Full Text] [Related]
46. The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing.
Zou SM; Li WH; Wang WM; Li WB; Shi SS; Ying JM; Lyu N
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2149-2159. PubMed ID: 30171333
[TBL] [Abstract][Full Text] [Related]
47. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
Fujiyoshi K; Yamamoto G; Takenoya T; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Anticancer Res; 2017 Jan; 37(1):239-247. PubMed ID: 28011498
[TBL] [Abstract][Full Text] [Related]
48. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis.
Cejas P; López-Gómez M; Aguayo C; Madero R; de Castro Carpeño J; Belda-Iniesta C; Barriuso J; Moreno García V; Larrauri J; López R; Casado E; Gonzalez-Barón M; Feliu J
PLoS One; 2009 Dec; 4(12):e8199. PubMed ID: 20020061
[TBL] [Abstract][Full Text] [Related]
49. Double
Deshwar A; Margonis GA; Andreatos N; Barbon C; Wang J; Buettner S; Wagner D; Sasaki K; Beer A; Løes IM; Pikoulis E; Damaskos C; Garmpis N; Kamphues K; He J; Kaczirek K; Poultsides G; Lønning PE; Mischinger HJ; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
Anticancer Res; 2018 May; 38(5):2891-2895. PubMed ID: 29715113
[TBL] [Abstract][Full Text] [Related]
50. Clinical and genetic determinants of ovarian metastases from colorectal cancer.
Ganesh K; Shah RH; Vakiani E; Nash GM; Skottowe HP; Yaeger R; Cercek A; Lincoln A; Tran C; Segal NH; Reidy DL; Varghese A; Epstein AS; Sonoda Y; Chi D; Guillem J; Temple L; Paty P; Hechtman J; Shia J; Weiser M; Aguilar JG; Kemeny N; Berger MF; Saltz L; Stadler ZK
Cancer; 2017 Apr; 123(7):1134-1143. PubMed ID: 27875625
[TBL] [Abstract][Full Text] [Related]
51. KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study.
Dadduzio V; Basso M; Rossi S; Cenci T; Capodimonti S; Strippoli A; Orlandi A; Cerchiaro E; Schinzari G; Cassano A; Martini M; Barone C
Mol Diagn Ther; 2016 Feb; 20(1):65-74. PubMed ID: 26610798
[TBL] [Abstract][Full Text] [Related]
52. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
Macerelli M; Caramella C; Faivre L; Besse B; Planchard D; Polo V; Ngo Camus M; Celebic A; Koubi-Pick V; Lacroix L; Pignon JP; Soria JC
Lung Cancer; 2014 Mar; 83(3):383-8. PubMed ID: 24439569
[TBL] [Abstract][Full Text] [Related]
53. Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status.
Tsilimigras DI; Hyer JM; Bagante F; Guglielmi A; Ruzzenente A; Alexandrescu S; Poultsides G; Sasaki K; Aucejo F; Pawlik TM
J Am Coll Surg; 2021 Apr; 232(4):590-598. PubMed ID: 33383214
[TBL] [Abstract][Full Text] [Related]
54. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.
Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D
Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653
[TBL] [Abstract][Full Text] [Related]
55. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
56. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
[TBL] [Abstract][Full Text] [Related]
57. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
Tie J; Lipton L; Desai J; Gibbs P; Jorissen RN; Christie M; Drummond KJ; Thomson BN; Usatoff V; Evans PM; Pick AW; Knight S; Carne PW; Berry R; Polglase A; McMurrick P; Zhao Q; Busam D; Strausberg RL; Domingo E; Tomlinson IP; Midgley R; Kerr D; Sieber OM
Clin Cancer Res; 2011 Mar; 17(5):1122-30. PubMed ID: 21239505
[TBL] [Abstract][Full Text] [Related]
58. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
Mizuno T; Cloyd JM; Vicente D; Omichi K; Chun YS; Kopetz SE; Maru D; Conrad C; Tzeng CD; Wei SH; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2018 May; 44(5):684-692. PubMed ID: 29551247
[TBL] [Abstract][Full Text] [Related]
59. KRAS Mutation Predicted More Mirometastases and Closer Resection Margins in Patients with Colorectal Cancer Liver Metastases.
Zhang Q; Peng J; Ye M; Weng W; Tan C; Ni S; Huang D; Sheng W; Wang L
Ann Surg Oncol; 2020 Apr; 27(4):1164-1173. PubMed ID: 31720935
[TBL] [Abstract][Full Text] [Related]
60. Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases.
Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Aulicino M; Vaira M; De Franciscis S; D'Acapito F; Carboni F; Milone E; Donini A; Fugazzola P; Faviana P; Sorrentino L; Pizzolato E; Cenzi C; Del Bianco P; Sommariva A
ESMO Open; 2024 Apr; 9(4):102976. PubMed ID: 38613907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
